Acusphere, Inc., a specialty pharmaceutical company, develops new drugs and formulations of existing drugs using its proprietary porous microparticle technology in the United States. Its porous microparticle technology enables to control the size and porosity of particles, including nanoparticles and microparticles. The company primarily develops products in the areas of cardiology, oncology, and asthma. Its products include AI-700, an ultrasound contrast agent, which is in Phase III clinical development for the detection of coronary heart disease; AI-850, a Phase I clinical trial completed product that utilizes hydrophobic drug delivery system to improve the dissolution rate of a cancer...